Going back to this idea, I was just reading an article on Yersinia and found this:
The incidence of reactive arthritis following
Y. enterocolitica infection is very high among adults in Scandinavia, where it is estimated to be 10 to 30% (
20). The incidence is much lower in most other countries, including the United States. The most commonly affected joints are the knees and ankles; but other joints, such as the toe, finger, and wrist joints, can be involved. In most cases, two to four joints become involved sequentially and asymmetrically over a period of a few days to 2 weeks. Monoarticular arthritis occurs less commonly. In two-thirds of cases, the acute arthritis persists for 1 to 4 months. Chronic joint disease or ankylosing spondylitis occurs rarely. Subsequent complications of
Y. enterocolitica infections that occur less often include reactive uveitis, iritis, conjunctivitis, glomerulonephritis, and urethritis. Reiter's syndrome (arthritis, conjunctivitis, and urethritis) is seen in only 5 to 10% of patients with yersinia-induced arthritis (
4).
So Scandinavia leads in ReA too! From what I understand of what Prof. Edwards has told me, ReA is a MALT-associated T-cell disease, governed by HLA-B27 subtypes. It seems slightly surprising to me then that it the incidence is higher in Scandinavia, as are other, unrelated autoimmune diseases. Of course, this could just be bad luck on the Scandinavians part, but I wonder if the genetic contributions for these different types of autoimmune disease overlap?
That brings me on to my second idea. From what I´ve read (and contrary to Prof. Edward´s opinion), I believe that ReA is caused by the persistence of the triggering organism, and that it is also possible to have an chronic Yersinia infection without ReA (this is what I think I´ve got). So it seems to me that ME (ICC) is caused by a chronic infection, plus the autoimmune/immunological problems caused by this infection. If that is the case, I would expect Scandinavia to have more ME cases with a large autoimmune component, and that these cases would on average be sicker than the cases with a small autoimmune component (I have heard reports that Scandinavia has a lot of severe ME cases, although this could also be due to differences in climate, latitude, etc). Finally, as was suggested above, I would expect Rituximab to be more effective in Scandinavia.